1 / 61

ANXIOLYTICS & SEDATIVE ,HYPNOTICS

ANXIOLYTICS & SEDATIVE ,HYPNOTICS. Manifestations of anxiety :. Verbal complaints. The patient says he/she is anxious, nervous, edgy. Somatic and autonomic effects . The patient is restless and agitated, has tachycardia, increased sweating, weeping and often gastrointestinal disorders.

jagger
Télécharger la présentation

ANXIOLYTICS & SEDATIVE ,HYPNOTICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANXIOLYTICS & SEDATIVE ,HYPNOTICS

  2. Manifestations of anxiety: • Verbal complaints. The patient says he/she is anxious, nervous, edgy. • Somatic and autonomic effects. The patient is restless and agitated, has tachycardia, increased sweating, weeping and often gastrointestinal disorders. • Social effects. Interference with normal productive activities.

  3. Pathological Anxiety Generalized anxiety disorder (GAD): People suffering from GAD have general symptoms of motor tension, autonomic hyperactivity, etc. for at least one month. Phobic anxiety: Simple phobias. Agoraphobia, fear of animals, etc. Social phobias. Panic disorders: Characterized by acute attacks of fear as compared to the chronic presentation of GAD. Obsessive-compulsive behaviors: These patients show repetitive ideas (obsessions) and behaviors (compulsions).

  4. Causes of Anxiety 1). Medical: • Respiratory • Endocrine • Cardiovascular • Metabolic • Neurologic.

  5. Causes of Anxiety 2). Drug-Induced: • Stimulants • Amphetamines, cocaine, TCAs, caffeine. • Sympathomimetics • Ephedrine, epinephrine, pseudoephedrine phenylpropanolamine. • Anticholinergics\Antihistaminergics • Trihexyphenidyl, benztropine, meperidine diphenhydramine, oxybutinin. • Dopaminergics • Amantadine, bromocriptine, L-Dopa, carbid/levodopa.

  6. Causes of Anxiety • Miscellaneous: • Baclofen, cycloserine, hallucinogens, indomethacin. 3). Drug Withdrawal: • BDZs, narcotics, BARBs, other sedatives, alcohol.

  7. Anxiolytics Strategy for treatment Reducing anxiety without causing sedation.

  8. Anxiolytics • Benzodiazepines (BZDs). • Barbiturates (BARBs). • 5-HT1A receptor agonists. • 5-HT2A, 5-HT2C & 5-HT3 receptor antagonists. If ANS symptoms are prominent: • ß-Adrenoreceptor antagonists (propranolol). • 2-AR agonists (clonidine).

  9. Anxiolytics • Other Drugs with anxiolytic activity. • TCAs (Fluvoxamine). Used for Obsessive compulsive Disorder. • MAOIs. Used in panic attacks. • Antihistaminic agents. Present in over the counter medications. • Antipsychotics (Ziprasidone).

  10. Sedative/Hypnotics • A hypnotic should produce, as much as possible, a state of sleep that resembles normal sleep.

  11. Properties of Sedative/Hypnotics in Sleep 1) The latency of sleep onset is decreased (time to fall asleep). 2) The duration of stage 2 NREM sleep is increased. 3) The duration of REM sleep is decreased. 4) The duration of slow-wave sleep (when somnambulism and nightmares occur) is decreased. Tolerance occurs after 1-2 weeks.

  12. Sedative/Hypnotics • Benzodiazepines (BZDs): Alprazolam, diazepam, oxazepam, triazolam 2) Barbiturates: Pentobarbital, phenobarbital 3) Alcohols: Ethanol, chloral hydrate, paraldehyde, trichloroethanol, 4) Imidazopyridine Derivatives: Zolpidem 5) Pyrazolopyrimidine Zaleplon

  13. Sedative/Hypnotics 6) Propanediol carbamates: Meprobamate 7) Piperidinediones Glutethimide • Azaspirodecanedione Buspirone 9) -Blockers** Propranolol 10) 2-AR partial agonist** Clonidine

  14. Sedative/Hypnotics Others: 11) Antyipsychotics ** Ziprasidone 12) Antidepressants ** TCAs, SSRIs 13) Antihistaminic drugs ** Dephenhydramine, Hydroxyzine

  15. Sedative/Hypnotics All of the anxiolytics/sedative/hypnotics should be used only for symptomatic relief. ************* All the drugs used alter the normal sleep cycle and should be administered only for days or weeks, never for months. ************ USE FOR SHORT-TERM TREATMENT ONLY!!

  16. SEDATIVE/HYPNOTICSANXYOLITICS GABAergic SYSTEM

  17. Sedative/Hypnotics The benzodiazepines are the most important sedative hypnotics. Developed to avoid undesirable effects of barbiturates (abuse liability).

  18. Benzodiazepines • Diazepam • Chlordiazepoxide • Triazolam • Lorazepam • Alprazolam • Clorazepate => nordiazepam • Halazepam • Clonazepam • Oxazepam • Prazepam

  19. Barbiturates • Phenobarbital • Pentobarbital • Amobarbital • Mephobarbital • Secobarbital • Aprobarbital

  20. NORMAL  ANXIETY _________  _________________ SEDATION  HYPNOSIS  Confusion, Delirium, Ataxia  Surgical Anesthesia  COMA  DEATH

  21. Respiratory Depression BARBS BDZs Coma/ Anesthesia Ataxia RESPONSE Sedation Anticonvulsant Anxiolytic DOSE

  22. Respiratory Depression BARBS Coma/ Anesthesia BDZs Ataxia RESPONSE Sedation Anticonvulsant Anxiolytic DOSE

  23. GABAergic SYNAPSE glucose glutamate GAD GABA Cl-

  24. GABA-A Receptor BDZs • Oligomeric (abdgepr) glycoprotein. • Major player in Inhibitory Synapses. • It is a Cl- Channel. • Binding of GABA causes the channel to open and Cl- to flow into the cell with the resultant membrane hyperpolarization. BARBs GABA AGONISTS   d  e

  25. Mechanisms of Action 1) Enhance GABAergic Transmission  frequency of openings of GABAergic channels. Benzodiazepines  opening time of GABAergic channels. Barbiturates  receptor affinity for GABA. BDZs and BARBS

  26. Patch-Clamp Recording of Single Channel GABA Evoked Currents From Katzung et al., 1996

  27. Benzodiazepines PHARMACOLOGY • BDZs potentiate GABAergic inhibition at all levels of the neuraxis. • BDZs cause more frequent openings of the GABA-Cl- channel via membrane hyperpolarization, and increased receptor affinity for GABA. • BDZs act on BZ1 [1] (1 and 2 subunit-containing) and BZ2[2] (5 subunit-containing) receptors. • May cause euphoria, impaired judgement, loss of self control and anterograde amnesic effects.

  28. Pharmacokinetics of Benzodiazepines • Although BDZs are highly protein bound (60-95%), few clinically significant interactions.* • High lipid solubility  high rate of entry into CNS  rapid onset. *The only exception is chloral hydrate and warfarin

  29. CNS Effects (Rate of Onset) Lipid solubility

  30. Pharmacokinetics of Benzodiazepines • Hepatic metabolism. Almost all BDZs undergo microsomal oxidation (N-dealkylation and aliphatic hydroxylation) and conjugation (to glucoronides). • Rapid tissue redistribution long acting  long half lives and elimination half lives (from 10 to > 100 hrs). • All BDZs cross the placenta • detectable in breast milk  may exert depressant effects on the CNS of the lactating infant.

  31. Pharmacokinetics of Benzodiazepines • Many have active metabolites with half-lives greater than the parent drug. • Prototype drug is diazepam (Valium), which has active metabolites (desmethyl-diazepam and oxazepam) and is long acting (t½ = 20-80 hr). • Differing times of onset and elimination half-lives (long half-life => daytime sedation).

  32. Biotransformation of Benzodiazepines

  33. Biotransformation of Benzodiazepines • the kinetics of the parent drug may not reflect the time course of the pharmacological effect. • Estazolam, oxazepam, and lorazepam, which are directly metabolized to glucoronides have the least residual (drowsiness) effects. • All of these drugs and their metabolites are excreted in urine.

  34. Properties of Benzodiazepines • BDZs have a wide margin of safety if used for short periods. Prolonged use may cause dependence. • BDZs have little effect on respiratory or cardiovascular function compared to BARBS and other sedative-hypnotics.

  35. Side Effects of Benzodiazepines • Related primarily to the CNS depression and include: drowsiness, excess sedation, impaired coordination, nausea, vomiting, confusion and memory loss. Tolerance develops to most of these effects. • Dependence with these drugs may develop. • Serious withdrawal syndrome can include convulsions and death.

  36. Sedative/Hypnotics • They produce a pronounce, graded, dose-dependent depression of the central nervous system.

  37. Toxicity/Overdose with Benzodiazepines • Drug overdose is treated with flumazenil (a BDZ receptor antagonist, short half-life), but respiratory function should be adequately supported and carefully monitored. • Seizures and cardiac arrhythmias may occur following flumazenil administration when BDZ are taken with TCAs. • Flumazenil is not effective against BARBs overdose.

  38. Drug-Drug Interactions with BDZs • BDZ's have additive effects with other CNS depressants (narcotics), alcohol => have a greatly reduced margin of safety. • BDZs reduce the effect of antiepileptic drugs. • Combination of anxiolytic drugs should be avoided. • Concurrent use with OTC antihistaminic and anticholinergic drugs as well as the consumption of alcohol should be avoided. • SSRI’s and oral contraceptives decrease metabolism of BDZs.

  39. Pharmacokinetics of Barbiturates • Rapid absorption following oral administration. • Rapid onset of central effects. • Extensively metabolized in liver (except phenobarbital), however, there are no active metabolites. • Phenobarbital is excreted unchanged. Its excretion can be increased by alkalinization of the urine.

  40. Pharmacokinetics of Barbiturates • In the elderly and in those with limited hepatic function, dosages should be reduced. • Phenobarbital and meprobamate cause autoinduction of liver enzymes.

  41. Properties of Barbiturates Mechanism of Action. • They increase the duration of GABA-gated channel openings. • At high concentrations may be GABA-mimetic. Less selective than BDZs, they also: • Depress actions of excitatory neurotransmitters. • Exert nonsynaptic membrane effects.

  42. Toxicity/Overdose • Strong physiological dependence may develop upon long-term use. • Depression of the medullary respiratory centers is the usual cause of death of sedative/hypnotic overdose. Also loss of brainstem vasomotor control and myocardial depression.

  43. Toxicity/Overdose • Withdrawal is characterized by increase anxiety, insomnia, CNS excitability and convulsions. • Drugs with long-half lives have mildest withdrawal. • Drugs with quick onset of action are most abused. • No medication against overdose with BARBs. • Contraindicated in patients with porphyria.

  44. Sedative/Hypnotics Tolerance and excessive rebound occur in response to barbiturate hypnotics.

  45. Miscellaneous Drugs • Buspirone • Chloral hydrate • Hydroxyzine • Meprobamate (Similar to BARBS) • Zolpidem (BZ1 selective) • Zaleplon (BZ1 selective)

  46. BUSPIRONE • Most selective anxiolytic currently available. • The anxiolytic effect of this drug takes several weeks to develop => used for GAD. • Buspirone does not have sedative effects and does not potentiate CNS depressants. • Has a relatively high margin of safety, few side effects and does not appear to be associated with drug dependence. • No rebound anxiety or signs of withdrawal when discontinued.

More Related